Phibro Animal Health Corporation Class A Common Stock (PAHC)

FairStock Score: 60/100 — STEADY

Key Financials

Strengths

• Generates $22 million in annual free cash flow (1.0% yield on market cap)
• High return on equity of 31.8% demonstrating efficient capital deployment
• Revenue growth of 20.9% demonstrates strong top-line momentum

Concerns

• Trades significantly above Graham Number ($20) with negative 166% margin of safety—limited downside protection
• High leverage at 2.33x debt-to-equity increases financial risk and interest expense burden

AI Analysis

Phibro Animal Health Corporation Class A Common Stock is a small-cap healthcare company valued at $2.2 billion. The business generates $1.5 billion in annual revenue with a 1.9% net margin and $22 million in free cash flow. From a quality standpoint, Phibro shows solid Piotroski F-Score of 6/9 and Altman Z-Score of 2.4 in the grey zone. On valuation, the stock is reasonably priced at 24.2x earnings, with trades far above its Graham Number ($20) with no margin of safety. Growth dynamics show revenue growing at 20.9% and profit growth of 762.1%. Our composite FairStock Score of 60/100 reflects above-average fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

Phibro's 21% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. With $22 million in annual free cash flow (1.0% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Elevated leverage at 2.3x D/E means rising interest rates or revenue weakness could strain debt covenants and force asset sales at distressed prices. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer